- Previous Close
0.7300 - Open
0.7300 - Bid --
- Ask --
- Day's Range
0.7120 - 0.7300 - 52 Week Range
0.4030 - 1.0400 - Volume
9,459 - Avg. Volume
46,943 - Market Cap (intraday)
219.09M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Sep 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.90
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
www.sensorion.comRecent News: ALSEN.PA
View MorePerformance Overview: ALSEN.PA
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALSEN.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALSEN.PA
View MoreValuation Measures
Market Cap
219.09M
Enterprise Value
134.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
30.81
Price/Book (mrq)
2.63
Enterprise Value/Revenue
25.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.67%
Return on Equity (ttm)
-50.73%
Revenue (ttm)
6.15M
Net Income Avi to Common (ttm)
-23.67M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
87.34M
Total Debt/Equity (mrq)
2.82%
Levered Free Cash Flow (ttm)
-15.32M